PEA400 Palmitoylethanolamide 400mg

Helps relieve chronic pain • 120 Capsules

Preferred Nutrition PEA 400 mg is a chronic pain relief formula made from fractionated non-GMO safflower seed oil. Studies have shown that palmitoylethanolamide (PEA), a fatty-acid-like compound, offers analgesic, neuroprotective, and anti-neuroinflammatory benefits. PEA occurs naturally in certain foods and is made within the body as part of the endocannabinoid system. This formula features micronized PEA for improved solubility and absorption.

Benefits

• Helps relieve chronic pain
• Features naturally produced PEA from fractionated non-GMO safflower seed oil
• Micronized for effective solubility and absorption by the body
• Provides 1200 mg of PEA per day, the same dose supported by clinical studies

Recommended adult dose: 3 capsules daily or as directed by a health care practitioner. For use beyond 4 months, consult a health care practitioner

Non-medicinal: Gelatin capsule (gelatin, purified water), microcrystalline cellulose, vegetable grade magnesium stearate (lubricant), silica, stearic acid.

This product does not contain artificial preservatives, colours, or sweeteners; no dairy, starch, sugar, wheat, gluten, yeast, soy, corn, egg, fish, shellfish, salt, tree nuts, or genetically modified genes or proteins.

RESEARCH
Palmitoylethanolamide (PEA) is a type of lipid found in foods such as egg yolks, safflower lecithin, soybeans, and peanuts. The body itself also produces some PEA for analgesic, neuroprotective, and antineuroinflammatory benefits. In clinical trials, PEA has been shown to reduce pain levels from a variety of chronic conditions (where pain persists for at least six months). This includes chronic pain not sufficiently controlled by standard therapies (Lang-Illievich et al., 2023).

A double-blind, placebo-controlled trial with more than 600 participants with radicular compression of the sciatic nerve compared PEA (300 or 600 mg per day) to a placebo for three weeks. At the 600 mg dose, participants had an average pain reduction of more than 50% (from 7.1 to 2.1) on a visual analogue scale (VAS) (Keppel Hesselink & Kopsky, 2015).

Similar benefits were seen in a small study involving adults with carpal tunnel syndrome. Patients taking 1200 mg of PEA daily saw greater benefits in distal motor latency compared to ones taking 600 mg daily, suggesting a dose-dependent effect (Conigliaro et al., 2011). 

An observational trial involved 610 participants with pain of more than six months duration related to a wide variety of conditions. Patients were given PEA at a dose of 600 mg twice daily for three weeks, followed by a dose of once daily for four weeks. PEA reduced the mean numeric rating scale of pain intensity in all patients who completed 
the study from a baseline mean of 6.4 to 2.5 by the end of the study. Importantly, PEA reduced pain regardless of etiology when used as a stand-alone treatment or in combination with other medications, and with no adverse effects (Gatti et al., 2012). 

In a triple-blind trial involving adults with temporomandibular joint (TMJ) osteoarthritis or arthralgia, PEA was given at a dose of 300 mg in the morning and 600 mg in the evening for one week. This was followed by a dose of 300 mg twice per day for one additional week. Significant improvements were seen for the PEA group compared to the group with standard treatment, in both maximum mouth opening and pain, with no adverse effects in the PEA group (Marini et al., 2012).

Preferred Nutrition